Pesquisar
Femasys Inc
FEMYAdicionar à lista de desejos
2.560USD
0.0000.00%
Horário de mercado 09/23, 13:36（ET）
7.73MValor de mercado
PerdaP/L TTM
Sobre o Femasys Inc Empresa
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Femasys Inc Perfil
Código da empresaFEMY
Nome da EmpresaFemasys Inc
Data de listagemJun 18, 2021
CEOLee-Sepsick (Kathy)
Número de funcionários69
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 18
Endereço3950 Johns Creek Court
CidadeSUWANEE
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal30024
Telefone17705003910
Sitehttps://www.femasys.com/
Código da empresaFEMY
Data de listagemJun 18, 2021
CEOLee-Sepsick (Kathy)
Executivos da empresa Femasys Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
4.00
--
Ms. Kelley Nicholas
Ms. Kelley Nicholas
Chief Commercial Officer
Chief Commercial Officer
4.00
--
Mr. Charles E. Larsen
Mr. Charles E. Larsen
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Edward Uzialko, Jr.
Mr. Edward Uzialko, Jr.
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Ms. Kathy Lee-Sepsick
Ms. Kathy Lee-Sepsick
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
37.27K
+41.93%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Mr. John Canning
Mr. John Canning
Chief Operating Officer
Chief Operating Officer
5.88K
+74.47%
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Dr. Kenneth D. Eichenbaum, M.D.
Dr. Kenneth D. Eichenbaum, M.D.
Independent Director
Independent Director
1.25K
--
Perguntas frequentes
Quem são os cinco principais acionistas de Femasys Inc?
Os cinco principais acionistas de Femasys Inc são: Ms. Kathy Lee-Sepsick
Quantas instituições possuem ações da Femasys Inc (FEMY)?
Em 2026Q1, 64 instituições possuíam ações da Femasys Inc, com valor de mercado aproximado de 6.18M, representando 10.23% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em 1191594.00.